—Hippocrates (1) The need of proper anticoagulation for cardioversion of atrial fibrillation
(AF) episodes with duration $48 h is well established. Nonanticoagulated patients carry a …

Restoring sinus rhythm either with pharmacological or electrical therapies is a desirable end-
point, at least in certain subsets of patients with atrial fibrillation. It may be achieved in 70 …

Currently, there is no unified consensus on short-term anticoagulation after cardioversion of
atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this …

Aims Single oral dose anti-arrhythmic drugs (AADs) are used to cardiovert recent-onset
atrial fibrillation (AF); however, the optimal agent is uncertain. Methods We performed a …

Focuses on the issues to be considered in deciding whether and when to apply
cardioversion in chronic atrial fibrillation (AF). Range of pharmacological and electrical …

Background: Atrial fibrillation is the most common sustained cardiac arrhythmia and has an
important impact on costs of medical assistance. Traditional interventions to convert atrial …

Background: Data on sex differences in terms of action of antiarrhythmic agents (AADs) are
limited. This study aimed to evaluate the clinical profile of patients with atrial fibrillation (AF) …

In patients with atrial fibrillation (AF), a rhythm–control strategy may be adopted when there
are unacceptable symptoms from AF, failure of rate control, and/or the presence of …

Atrial fibrillation (AF) is the most frequent chronic arrhythmia worldwide, and it is associated
with significant morbidity and mortality, making it a considerable burden both to patients and …

Background Antiarrhythmic drugs prolong the atrial action potential and refractory period,
and thereby prevent recurrent atrial fibrillation after cardioversion. The atrial action potential …